Hebei Newtherapy BIo-Pharma technology
CompanyChina
Hebei Newtherapy BIo-Pharma technology develops one asset, in phase 1 (Umbilical Cord Derived Mesenchymal Stem Cells in Parkinson's disease). Mostly cell therapy; based in China.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 0
- Signals
Pipeline
1Umbilical Cord Derived Mesenchymal Stem Cells
Phase 1, Cell therapy, Parkinson's disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Signals1
- Similar companies6